Combining Bevacizumab with Endostatin Gets Better Antitumor Efficacy in Vivo in Lung Cancer Animal Model

Background and objective The aim of this study is to investigate difference of antiangiogenesis ablility and interaction about bevacizumab and endostatin in vivo in lung cancer animal model. Methods First, we construct a Balb/c mice model with A549 lung adenocarcinoma cell. Then, we divide the mice into four groups randomly. Every group has six mice. Control group: mice injected with normal saline every day aroud the tumor. Endostatin group: mice injected with endostatin (Recombinant endostatin) injection (3 mg/kg) every day Peritumoral. Bevacizumab group: mice injected with bevacizumab twice a week (biw/5 mg/kg) Peritumoral. Combing group: mice were injected with endostatin and bevacizumab (dose just like single drug group). After 16 days, we executed mice and got the tumor tissue for next analysis. Results Based on this experiment, we found bevacizumab and endostatin expressed the ability for inhibiting tumor growth in vivo. Bevacizumab was more powerful (52.36% vs 38.68%). Combining bevacizumab with endostatin could get better results (64.15%) than single drug did. Bevacizumab played the role by inhibiting VEGF-A expression (60.8%). Endostatin took effect by inhibiting VEGF-A/C (14.6%, 30.3%). Combining group present better antitumor efficacy than any single drug group did. (79.7%, 44.2%). Conclusion Both bevacizumab and endostatin present the antiangiogenesis ability in vivo of lung cancer animal model. In our test, bevacizumab show better ability in inhibiting tumor growth than endostatin does. Additional, combing bevacizumab with endostatin reveal better potential to inhibit tumor growth than single drug does.

Abstract licence: CC BY

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.